JY BioMed is advancing a diversified portfolio of investigational therapies across immuno-oncology, regenerative medicine, and targeted biologics. Our proprietary platforms—including gamma delta T cell therapies, dendritic cell-based vaccines, mesenchymal stem cell products, and antibody-drug conjugates—are designed to address critical unmet medical needs.

​

With a strong scientific foundation, early clinical progress, and scalable manufacturing collaborations, we are positioned at the forefront of cell-based and exosome-based innovation. Our focus on global regulatory readiness, ethical development practices, and sustainable growth underscores our long-term value creation strategy. We are committed to advancing transformative science while building meaningful opportunities for patients, partners, and stakeholders.

​

Key Investment Highlights

• Broad and diversified technology platforms across high-growth sectors

• Proprietary cell expansion and exosome production processes

• Early clinical progress with UC-MSC program in Phase 1 evaluation

• Strong alignment with global regulatory and sustainability standards

• Leadership team with proven expertise in biotech innovation and clinical translation

Regulatory Disclaimer

Statements regarding investment highlights are for informational purposes only and do not constitute investment advice or guarantees of future results. All development programs are subject to scientific, regulatory, and operational risks.